The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML.
 
Michael Richard Grunwald
Stock and Other Ownership Interests - Medtronic
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; ARIAD; Incyte; Pfizer
Research Funding - Amgen (Inst); FORMA Therapeutics (Inst); Incyte (Inst); Janssen (Inst)
 
Daniel T. Peters
No Relationships to Disclose
 
Myra M. Robinson
No Relationships to Disclose
 
Michael Keith Allister Zimmerman
No Relationships to Disclose
 
Jing Ai
No Relationships to Disclose
 
Thomas Gregory Knight
No Relationships to Disclose
 
Peter N. Lalli
No Relationships to Disclose
 
Jared G. Block
Employment - Alexion Pharmaceuticals; Carolinas Pathology Group
Stock and Other Ownership Interests - Celligent Diagnostics
Honoraria - Alexion Pharmaceuticals
Speakers' Bureau - Alexion Pharmaceuticals
 
Elton Travis Smith
Employment - Carolinas Pathology Group; Celligent Diagnostics
Stock and Other Ownership Interests - Carolinas Pathology Group; Celligent Diagnostics
 
Edward H. Lipford
Employment - Carolinas Pathology Group
Stock and Other Ownership Interests - Carolinas Pathology Group; Celligent Diagnostics
 
Edward Alan Copelan
No Relationships to Disclose
 
James Thomas Symanowski
Consulting or Advisory Role - Endocyte (Inst); Lilly; Ra Pharma (Inst)
Research Funding - Bayer (Inst); Celgene (Inst); Novocure (Inst); Pfizer (Inst)
 
Jonathan Michael Gerber
Consulting or Advisory Role - Alexion Pharmaceuticals; Seagen; Spectrum Pharmaceuticals
Research Funding - Janssen Research & Development (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No. 9,012,215